Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- N1,N8-dihydroxy-octanediamide
- Correlated keywords
- histones deacetylases HDACs inhibitors genes expression regulation epigenetics nucleosomes HDAC1 HDAC3 differentiation cells cycle arrest apoptosis cancers suberodihydroxamic acid suberoyl bishydroxamic acid inhibited inhibition Warner-Lambert Brand of Mefenamic Acid Warner Lambert Brand of Mefenamic Acid Pharmascience Brand of Mefenamic Acid First Horizon Brand of Mefenamic Acid Parke Davis Brand of Mefenamic Acid Farmasierra Brand of Mefenamic Acid Ashbourne Brand of Mefenamic Acid Pinewood Brand of Mefenamic Acid Nu-Pharm Brand of Mefenamic Acid Nu Pharm Brand of Mefenamic Acid Chemidex Brand of Mefenamic Acid Gödecke Brand of Mefenamic Acid Clonmel Brand of Mefenamic Acid Antigen Brand of Mefenamic Acid Pfizer Brand of Mefenamic Acid Apotex Brand of Mefenamic Acid Rowa Brand of Mefenamic Acid Elan Brand of Mefenamic Acid APS Brand of Mefenamic Acid PMS-Mefenamic Acid PMS Mefenamic Acid Acid Mefenaminic Mefenaminic Acid Acid Mefenamic Mefenamic Acid Forte Ponstan Ponstan Forte Apo-Mefenamic Apo Mefenamic Nu-Mefenamic Nu Mefenamic ApoMefenamic NuMefenamic Pinalgesic Contraflam Ponalgic Parkemed Ponstel Ponstan Ponalar Mefacit Pontal Ponsyl Ponmel Dysman Coslan Mefic Mefac
- Product Overview:
Suberohydroxamic acid (SBHA) is a competitive histone deacetylase (HDAC) inhibitor that has been shown to inhibit HDAC1 (IC50 = 0.25 ?M) and HDAC3 (IC50 = 0.30 ?M).{17174} SBHA causes cell differentiation, cell cycle arrest, or apoptosis.{18561,18558,18559,18557,18556} HDAC inhibitors, including SBHA, act synergistically to kill cancer cells when used in combination with cytostatic drugs, allowing lower doses of both inhibitors and drugs to be used.{18560,18446}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.